明德生物：募集资金投资项目延期

Core Viewpoint - The company announced a non-public offering of shares, raising a net amount of 460 million yuan, which will be used for in vitro diagnostic product projects, healthcare information projects, and to supplement working capital [1] Group 1: Fundraising and Investment Plans - The company committed to invest 215 million yuan in the in vitro diagnostic product project, with 141 million yuan already invested, achieving a progress rate of 65.64% [1] - For the healthcare information project, the company committed to invest 121 million yuan, with only 20 million yuan invested so far, resulting in a progress rate of 16.43% [1] Group 2: Project Timeline Adjustments - Due to changes in the macro market environment, pharmaceutical industry policies, and customer demand, the company plans to extend the completion date of the two fundraising projects from December 31, 2025, to December 31, 2026 [1] - The extension is a prudent decision based on the company's actual operating conditions and does not alter the intended use of the raised funds, nor does it negatively impact the company's normal operations or shareholder interests [1]